Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
9 participants
INTERVENTIONAL
2020-04-25
2020-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019
NCT04338009
Treatment of Angiotensin Converting Enzyme Inhibitor-induced Angioedema
NCT04679311
Natriuresis-Guided Diuretic Therapy in Patients With Acute Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease
NCT06203236
ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
NCT04467931
Enhancing the Natriuretic Peptide System in HFpEF
NCT05279742
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
non-peptide group
This group will receive routine treatment and care for COVID-19.
No interventions assigned to this group
peptide group
This group will receive angiotensin peptide (1-7) supplementation in addition to routine treatment and care for COVID-19.
Biological/Vaccine: Angiotensin peptide (1-7) derived plasma
angiotensin peptide (1-7) derived plasma will be given to COVID-19 positive participants
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biological/Vaccine: Angiotensin peptide (1-7) derived plasma
angiotensin peptide (1-7) derived plasma will be given to COVID-19 positive participants
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* proven positive COVID-19
Exclusion Criteria
* genetic/chromosomal abnormalities
* any kind of history of previous adverse events with transfusion
* diagnosis of immune deficiency
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kanuni Sultan Suleyman Training and Research Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hasan Onal
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kanuni Sultan Suleyman Training and Research Hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KSSEAH--0059
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.